FDA Drops Guide for Bulk Compounding Animal Drugs in Facilities
Published Date: 8/28/2026
Notice
Summary
The FDA just dropped a draft guide for companies that make animal drugs from bulk ingredients in registered facilities. It explains when the FDA won’t step in, as long as these places follow good manufacturing rules. If you’re in this business, you’ve got until November 27, 2026, to share your thoughts before the guide goes final—so get ready to weigh in and maybe save some money by staying compliant!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Enforcement Discretion Extended to Registered Facilities
FDA's draft guidance GFI #256B describes circumstances under which the Agency generally does not intend to take enforcement action for compounding animal drug products from bulk drug substances (BDS) when done under Current Good Manufacturing Practice (CGMP) at federally-registered facilities (registered under section 503B(b) or 510(b)). The draft says this policy would apply for compounding for nonfood-producing animals, with or without patient-specific prescriptions, and for certain uses such as antidotes for food-producing animals or sedatives/anesthetics for free-ranging wildlife species, provided certain circumstances are present.
Estimated Recordkeeping Time Burden
FDA estimates recordkeeping related to documenting medical rationales will total 111,245 hours annually across about 7,508 recordkeepers and 5,562,234 records. FDA estimates 7,500 licensed veterinarians/pharmacist compounders (state-licensed pharmacies or Federal facilities) will generate about 5,556,306 records and that 8 federally-registered facilities will generate about 5,928 records, with an estimated 0.02 hours (1 minute) per record.
Labeling Recommendations for Compounded Animal Drugs
The draft guidance recommends pharmacists include basic labeling information on compounded animal drugs from BDS—such as name and strength of the drug, species, directions for use, compounder name/address/contact—and specific statements (for example, "This is a compounded drug. Not an FDA approved or indexed drug"). FDA states it believes including this basic label information is usual and customary and estimates no recordkeeping or labeling time burden for preparing such labels.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-17578, 30-Day Notice of Proposed Information Collection: Annual Report-J-NONIMMIGRANT Exchange Visitor Program
The Department of State has submitted the information collection described below to the Office of Management and Budget (OMB) for approval. In accordance with the Paperwork Reduction Act of 1995 we are requesting comments on this collection from all interested individuals and organizations. The purpose of this Notice is to allow 30 days for public comment.
Next: 2026-17585, Privacy Act of 1974; System of Records
In accordance with the requirements of the Privacy Act of 1974, as amended, (Privacy Act), the Federal Housing Finance Agency (FHFA or Agency) is proposing to modify an existing system of records titled, "Employee Benefits Records, FHFA-10." This system of records contains documentation pertaining to current and former FHFA employees and their spouses, domestic partners, dependents, and beneficiaries who are enrolled in, apply for, or participate in any FHFA employee benefits program including health club memberships; health, life, and other insurance programs; retirement savings programs; and other FHFA- sponsored benefit programs. The purpose of the system is to collect, maintain, and use the records necessary to administer and manage FHFA's employee benefits programs. The system supports the full lifecycle of benefits-related activities, and ensures the accurate processing of claims, reimbursements, contributions, payroll deductions, and benefit payments. The system also facilitates the recording and tracking of key program functions, including eligibility determinations, enrollments, changes in coverage, and termination of benefits. The proposed modifications include: revising the system security classification, system location, system manager, legal authorities for maintenance of the system, categories of individuals covered by the system, categories of records maintained in the system, and record source categories; the revision, removal, and addition of routine uses; removal of the Disclosure to Consumer Reporting Agencies section; updating the policies and practices for storage of records, the policies and practices for retention and disposal of records, and the administrative, technical, and physical safeguards; and minor updates for clarity and consistency.